Lung cancer remains the leading cause of cancer mortality in men and women in the US
and worldwide. About 90% of lung cancer cases are caused by smoking and the use of …

Abstract Introduction/Background An individual patient data metaanalysis was performed to
determine clinical outcomes, and to propose a risk stratification system, related to the …

Background We assessed the efficacy and safety of programmed cell death 1 (PD-1)
inhibition with pembrolizumab in patients with advanced non–small-cell lung cancer …

Background Ramucirumab is a human IgG1 monoclonal antibody that targets the
extracellular domain of VEGFR-2. We aimed to assess efficacy and safety of treatment with …

Abstract Background Tumor-associated macrophages (TAMs) play a critical role in
modulating the tumor microenvironment and promote tumor metastases. Our studies have …

CV9201 is an RNActive®-based cancer immunotherapy encoding five non-small cell lung
cancer-antigens: New York esophageal squamous cell carcinoma-1, melanoma antigen …

Systemic chemotherapy given at maximum tolerated doses (MTD) has been the mainstay of
cancer treatment for more than half a century. In some chemosensitive diseases such as …

Non–small cell lung cancer (NSCLC) is one of the most prevalent cancers and is
responsible for a large proportion of all cancer-related deaths. Current treatment options are …

The relationship between circular RNA (circRNA) and cancer stem cells (CSCs) is uncertain.
We have investigated the combined influence of CSCs, circRNA (hsa_circ_0003222), and …

Purpose: Reliable and reproducible methods for identifying PD-L1 expression on tumor cells
are necessary to identify responders to anti–PD-1 therapy. We tested the reproducibility of …